Zika fever and congenital Zika syndrome: An unexpected emerging arboviral disease

Jasper F.W. Chan a,b,c,d, Garnet K.Y. Choi d, Cyril C.Y. Yip d, Vincent C.C. Cheng d, Kwok-Yung Yuen a,b,c,d,*

a State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, China
b Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region, China
c Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, China
d Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, China

Accepted 20 February 2016
Available online 3 March 2016

Summary
Unlike its mosquito-borne relatives, such as dengue, West Nile, and Japanese encephalitis viruses, which can cause severe human diseases, Zika virus (ZIKV) has emerged from obscurity by its association with a suspected “congenital Zika syndrome”, while causing asymptomatic or mild exanthematous febrile infections which are dengue- or rubella-like in infected individuals. Despite having been discovered in Uganda for almost 60 years, <20 human cases were reported before 2007. The massive epidemics in the Pacific islands associated with the ZIKV Asian lineage in 2007 and 2013 were followed by explosive outbreaks in Latin America in 2015. Although increased mosquito breeding associated with the El Niño effect superimposed on global warming is suspected, genetic changes in its RNA virus genome may have led to better adaptation to mosquitoes, other animal reservoirs, and human. We reviewed the epidemiology, clinical manifestation, virology, pathogenesis, laboratory diagnosis, management, and prevention of this emerging infection. Laboratory diagnosis can be confounded by cross-reactivity with other circulating flaviviruses. Besides mosquito bite and transplacental transmission, the risk of other potential routes of transmission by transfusion, transplantation, sexual activity, breastfeeding, respiratory droplet, and animal bite is discussed. Epidemic
Introduction

Globalisation and urbanisation with increasingly frequent and large-scale movements of humans, animals, and commodities by aviation and water transport has led to the spread of previously geographically-restricted microbes and vectors to distant and isolated places. Recent examples of emerging viruses that have spilled over to other continents from their original localities via exportation of travel-related cases include coronaviruses (severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus), influenza viruses, and Ebola virus. Moreover, global warming and climate changes have redefined the geographical distributions of important vectors of arthropod-borne viruses (arboviruses), such as the Aedes mosquitoes, and facilitated the global spread of these viruses. Dengue virus (DENV), West Nile virus (WNV), and Chikungunya virus (CHIKV), have been introduced (WNV in 1999 and CHIKV in 2013) and/or spread rapidly in the western hemisphere in the past two decades. Zika virus (ZIKV) is an arbovirus that was little known before it caused a large outbreak on Yap Island of the Federated States of Micronesia in 2007. Even then, ZIKV was not considered as an important emerging pathogen because clinical disease was generally mild. The recent report of a possible association between ZIKV infection and an epidemic of microcephaly among neonates in Brazil has attracted global attention. The rapid spread of ZIKV beyond Africa and Asia to the Americas and Europe, and the potentially novel “congenital Zika syndrome” outbreak have led the World Health Organisation (WHO) to declare the ZIKV epidemic as a global public health emergency on 1 February 2016. It would therefore be important to review the current knowledge on the epidemiology, virology, clinical manifestations, and laboratory diagnosis of ZIKV infection, and most importantly, to formulate clinical management options with special reference to perinatal care and control measures based on comparisons made with other mosquito-borne arboviruses.

History and epidemiology

Important historical and epidemiological events

ZIKV (strain MR 766) was first isolated from the blood of a febrile sentinel rhesus monkey (Macaca mulatta), Rhesus 766, during a study on yellow fever virus (YFV) in Zika Forest of Uganda in April 1947 (Table 1). In 1948, ZIKV was isolated from Aedes africanus mosquitoes caught in Zika Forest, suggesting that the virus might be mosquito-borne. In 1954, ZIKV was isolated from the serum of a 10-year-old Nigerian girl who had fever and headache, implying its role as a possible human pathogen. Further virological and/or serological evidence of human ZIKV infection was reported in African (Uganda, Tanzania, Egypt, Central African Republic, Sierra Leone, and Gabon) and Asian (India, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia) countries. ZIKV infection remained relatively restricted geographically with less than 20 sporadic cases reported in these areas in the first 60 years after its discovery. In 2007, ZIKV emerged outside Africa and Asia for the first time and caused a major outbreak on Yap Island of the Federated State of Micronesia. Over 70% of the Yap residents who were ≥3 years were infected within 4 months. The attack rate of ZIKV infection in this outbreak was 14.6 per 1000 residents (range, 3.5—21.5 per 1000 residents). Subsequently, another major outbreak was reported in French Polynesia in October 2013. An estimated 30,000 humans (>11% of the French Polynesian population) were infected by ZIKV. ZIKV infection then spread from French Polynesia to other Pacific Islands including New Caledonia, Cook Islands, Vanuatu, and Solomon Islands. The first cases of human ZIKV infection in the western hemisphere occurred on Easter Island, Chile, in February 2014, possibly originating from French Polynesia during the annual Tapati festival. Phylogenetic analysis revealed that the NS5 gene sequence of the Chilean strains had 99.8% nucleotide and 100% amino acid identity to the French Polynesian strains. The epidemic continued to expand rapidly and autochthonous human cases were reported in many Latin American countries in the ensuing 2 years.

Brazil stands out as the hardest hit Latin American country with an estimated 500,000—1,500,000 cases of ZIKV infection since March 2015. Based on the close phylogenetic relationship between the South American strains and Asian and Oceania strains of ZIKV, the virus might have been introduced into Brazil by Asian travellers during the World Cup or participants from the Oceanic countries of the Va’a World Sprint Championship canoe race in the summer of 2014. The climate changes associated with El Niño in north and eastern South America in 2015 on the background trend of global warming might have facilitated the rapid spread of Aedes mosquitoes and ZIKV. Currently, >30 countries in Africa, Asia, South America, Oceania, and Micronesia have reported autochthonous cases of human ZIKV infection. Travel-related cases from endemic and epidemic regions were also reported in Europe, North America, Australia, and Japan. More worryingly, the Brazil Health Ministry reported the detection of an unusual increase in the number of cases of neonates with microcephaly in northeastern Brazil in October 2015, coinciding with the expanding ZIKV infection epidemic. Over 3000 suspected cases including some fatal cases were reported during the second half of 2015 alone. This represented a >20-fold increase in the rate of microcephaly as compared to previous years. On 24 November 2015, the French Polynesia health authorities also reported an unusual increase in the number of foetal and neonatal central nervous system malformations in 2014 and 2015.
Routes of transmission

Like other flaviviruses, ZIKV is mainly transmitted by mosquitoes. In addition to the sylvatic (enzootic) transmission cycle between the haematophagous mosquito vectors and susceptible primary vertebrate hosts, the recent large-scale epidemics suggest that ZIKV is also adapting to an urban transmission cycle. Among the various mosquito species, *Aedes* (*Stegomyia*) mosquitoes appear to be the most important vector for ZIKV transmission, although some *Anopheles*, *Culex*, *Eretmapodites*, and *Mansonoba* species have also been proposed as possible vectors (Table 2). The animal reservoirs of ZIKV are unclear. Non-human primates including *M. mulatta*, *Cercopithecus aethiops*, *C. ascanius schmidti*, *C. mona danti*, *C. albigena johnstoni*, *Chlorocebus sabaeus*, *Colobus abyssinicus*, *Erythrocebus patas*, and *Pongo pygmaeus*, and other mammals including zebras, elephants, and rodents, have been suggested as possible vertebrate hosts of ZIKV in Africa and Asia, based on virological and/or serological evidence of infection. *Ae. africanus* is the first mosquito species from which ZIKV was isolated, and

<table>
<thead>
<tr>
<th>Dates</th>
<th>Locations</th>
<th>Events</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 1947</td>
<td>Uganda</td>
<td>The first isolation of ZIKV from a febrile sentinel rhesus monkey (Rhesus 766).</td>
<td>16</td>
</tr>
<tr>
<td>1947–1948</td>
<td>Uganda</td>
<td>The first detection of neutralising antibodies to ZIKV in sentinel rhesus monkeys.</td>
<td>16, 54</td>
</tr>
<tr>
<td>January 1948</td>
<td>Uganda</td>
<td>The first isolation of ZIKV from <em>Aedes africanus</em>; mice inoculated intracerebrally with unfiltered supernatant of ZIKV-infected <em>Ae. africanus</em> became sick.</td>
<td>16, 59</td>
</tr>
<tr>
<td>1952 (archived samples)</td>
<td>Uganda</td>
<td>The first report of serum neutralising antibodies to ZIKV being detected in man in Uganda.</td>
<td>54</td>
</tr>
<tr>
<td>1954</td>
<td>Nigeria</td>
<td>The first isolation of ZIKV from human serum.</td>
<td>17</td>
</tr>
<tr>
<td>1956</td>
<td>Nigeria</td>
<td>ZIKV was successfully transmitted from artificially fed <em>Ae. aegypti</em> mosquitoes to mice and a monkey in laboratory setting.</td>
<td>55</td>
</tr>
<tr>
<td>1964</td>
<td>Uganda</td>
<td>The first well-documented report of occupationally-acquired (medical entomologist) human ZIKV infection.</td>
<td>117</td>
</tr>
<tr>
<td>1960–2006</td>
<td>Africa and Asia</td>
<td>&lt;20 sporadic cases reported in the literature; all in African and Asian countries.</td>
<td>19, 68, 118, 146</td>
</tr>
<tr>
<td>2007–2008</td>
<td>Yap Island, FSM</td>
<td>The first major ZIKV epidemic in an urban region with ~73% of the Yap population being infected in 4 months.</td>
<td>13</td>
</tr>
<tr>
<td>2009–2012</td>
<td>Africa, Asia, Europe, North America, and Australia</td>
<td>A small number of cases (including travel-related cases) reported.</td>
<td>39–41, 43, 47, 118, 147</td>
</tr>
<tr>
<td>October 2013</td>
<td>French Polynesia and other Pacific islands</td>
<td>The second major outbreak reported in the Pacific region with an estimated 30,000 persons (&gt;11% of the population) being infected; subsequently spread to other Pacific Islands including New Caledonia, Cook Islands, Vanuatu, Solomon Islands, and Easter Island.</td>
<td>28, 114, 147–149</td>
</tr>
<tr>
<td>March 2015</td>
<td>Brazil</td>
<td>The first autochthonous cases reported in Brazil; total estimated cases in Brazil ~500,000–1,500,000.</td>
<td>116, 121, 150, 151</td>
</tr>
<tr>
<td>October 2015</td>
<td>Brazil</td>
<td>An unusual increase in cases of neonates with microcephaly in northeastern Brazil with ~3000 cases including deaths (~20-fold increase in microcephaly rate from 2010).</td>
<td>14</td>
</tr>
<tr>
<td>October 2015</td>
<td>South America</td>
<td>Autochthonous cases reported in other South American countries.</td>
<td>51</td>
</tr>
<tr>
<td>1 February 2016</td>
<td>WHO</td>
<td>WHO declared the Zika virus epidemic as a global public health emergency.</td>
<td>15</td>
</tr>
<tr>
<td>5 February 2016</td>
<td>Global</td>
<td>&gt;30 countries in Africa, Asia, Latin America, and Oceania/Pacific islands, have reported autochthonous cases; and imported cases are reported in Europe and North America.</td>
<td>32, 38, 121</td>
</tr>
</tbody>
</table>

Abbreviations: FSM, Federated State of Micronesia; WHO, World Health Organisation; ZIKV, Zika virus.
<table>
<thead>
<tr>
<th>Mosquito species</th>
<th>Findings</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genus Aedes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ae. aegypti</td>
<td>Considered as the primary vector for ZIKV transmission; natural infection reported. <em>In vitro</em>: susceptible to ZIKV infection with a short extrinsic incubation period of 5 days.</td>
<td>25, 55-58</td>
</tr>
<tr>
<td>Ae. africanus</td>
<td>Natural infection: first mosquito species from which ZIKV was isolated from.</td>
<td>52, 54, 59</td>
</tr>
<tr>
<td>Ae. albopictus</td>
<td>Natural infection: <em>Ae. albopictus</em> reported (Gabon). <em>In vitro</em>: can be infected by and transmit &gt;20 different arboviruses including ZIKV. Natural infection reported.</td>
<td>61-64</td>
</tr>
<tr>
<td>Ae. apicoargenteus, Ae. flavicollis, Ae. fowleri, Ae. furcifer, Ae. grhami, Ae. hirsutus, Ae. Jamoti, Ae. metallicus, Ae. minutus, Ae. neoafriicanus, Ae. opok, Ae. taeniarostris, Ae. tarsalis, Ae. taylori, Ae. vittatus, Ae. dalzieli</td>
<td>Natural infection reported; phylogenetic analysis shows evidence to support its role as an important vector for ZIKV transmission in West Africa.</td>
<td>52</td>
</tr>
<tr>
<td>Ae. hensilli</td>
<td>Susceptible to ZIKV infection <em>in vitro</em>; the most abundant mosquito species on Yap Island (but no virus isolation was made from field-collected mosquitoes).</td>
<td>67</td>
</tr>
<tr>
<td>Ae. luteocephalus, Ae. vittatus</td>
<td>Natural infection reported; exhibited potential to transmit ZIKV <em>in vitro</em>.</td>
<td>25, 52, 57</td>
</tr>
<tr>
<td>Ae. unilineatus</td>
<td>Natural infection reported; susceptible to ZIKV infection <em>in vitro</em>.</td>
<td>25, 52</td>
</tr>
<tr>
<td><strong>Genus Anopheles</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>An. coustani, An. gambiae s.l.</td>
<td>Natural infection reported.</td>
<td>25, 52</td>
</tr>
<tr>
<td><strong>Genus Culex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cx. perfuscus</td>
<td>Natural infection reported.</td>
<td>52</td>
</tr>
<tr>
<td><strong>Genus Mansonia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ma. uniformis</td>
<td>Natural infection reported.</td>
<td>52</td>
</tr>
<tr>
<td><strong>Genus Eretmapodites</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Er. inornatus, Er. quinquevittatus</td>
<td>Natural infection reported.</td>
<td>100</td>
</tr>
</tbody>
</table>

Abbreviations: ZIKV, Zika virus.
is likely an important vector in the sylvatic transmission cycle of ZIKV. Inoculation of unfiltered supernatant of ZIKV-infected Ae. africanus into mice and rhesus macaques led to clinical disease and/or neutralising antibody response. Ae. hensilli and Ae. albopictus, which have much wider geographical distributions than other Aedes mosquitoes, are considered to be more important vectors in the urban transmission cycle of ZIKV. These Aedes mosquitoes are highly susceptible to ZIKV infection in vitro with potential for further transmission after an extrinsic incubation period of 5–10 days. They bite both indoors and outdoors, and mostly during daytime. Non-vector-borne transmission routes of ZIKV have been proposed (Table 3). Like other arboviruses, blood transfusion-related transmission of ZIKV is possible, especially in endemic regions or where blood products obtained from infected travellers immediately returning from endemic regions are used. ZIKV RNA was detected in the blood of 2.8% of the donors in French Polynesia during the epidemic. Sexual transmission of ZIKV appears highly probable, especially in patients presenting with haematospermia with infectious viral particles and RNA in semen. Notably, no other arboviruses have been associated with haematospermia or isolated from human semen. This might further complicate the control of the ZIKV epidemic, since most infected patients are asymptomatic. Inadvertent sexual transmission of ZIKV to the female partner may then lead to virus transmission to the foetus, which may be potentially associated with severe congenital anomalies. Besides transplacental transmission, perinatal transmission of ZIKV may also occur during delivery, via breastfeeding, and/or close contact after birth via exchange of saliva and other bodily fluids. ZIKV RNA could be detected in breast milk and saliva of infected women, although replicative virus particles have not been demonstrated. Perinatal transmission of other arboviruses, including DENV, CHIKV, WNV, and YFV, has also been reported. Other suspected routes of transmission of ZIKV infection are those reported for other flaviviruses. These include mucocutaneous exposure to the virus in infected blood or via monkey bite, haemodialysis, or organ transplantation. Particularly, as ZIKV may be shed in the urine of infected patients for more than 30 days, the virus can infect epidermal keratinocytes, skin fibroblasts in the subcutaneous layer, and the Langerhans cells. The keratinocytes and fibroblasts contain AXL, Tyro3, and TIM-1, which can serve as attachment factors or receptors for ZIKV. The Langerhans cells contain DC-SIGN, which can interact with TLR3 mRNA expression, and enhanced transcription of RIG-I and MDA5, which are known innate immune responses to RNA virus infection. This is followed by enhanced expression of interferon-alpha and -beta, and their downstream pathways of immune activation. Both types I and II interferons can suppress the viral load of infected cells. Moreover, ZIKV is capable of increasing its replication by the induction of autophagy in host cells. Thus, autophagy inhibitors can decrease the viral load of infected cells. Phylogenetic analysis suggests that ZIKV has likely emerged between 1892 and 1943 in Uganda. The two major lineages of ZIKV are the African (subdivided into West and East African) and Asian lineages, which are responsible for causing the majority of infections in Africa and Asia (as well as the Pacific and Americas), respectively. The single-stranded RNA genome of ZIKV has a size of 10,794 nucleotides encoding 3419 amino acids, with 2 flanking untranslated regions (5' and 3' UTRs) and a single long open reading frame encoding a polyprotein, which is cleaved into capsid (C), precursor of membrane (prM), envelope (E), and 7 non-structural (NS) proteins (5'-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3'). Reverse transcription-polymerase chain reaction (RT-PCR) using primers targeting the E or NS5 gene is a key laboratory diagnostic tool for ZIKV infection in the recent outbreaks. The E protein is a major virion surface protein that is involved in receptor binding and membrane fusion. The domain III of E protein contains a panel of antigenic epitopes that are important targets of serological assays, neutralising antibodies, and vaccines. Loss of the N154 glycosylation site in the E protein may be associated with adaptation to mosquito vectors and thus facilitate transmission. A single amino acid mutation in the E protein (E1-A226V) of CHIKV has been reported to be associated with increased fitness of the virus in Ae. albopictus and allows CHIKV to disseminate in regions lacking the typical Ae. aegypti vector. The recent spread of the Asian lineage of ZIKV to Oceania and the Americas may be associated with significant NS1 codon usage adaptation to human housekeeping genes, which could facilitate viral replication and increase viral titres. Mutations in the E and NS1 genes should be detected in ZIKV strains causing the current epidemic.

When an infected Aedes mosquito bites an infected patient, it ingests a blood meal containing ZIKV. As in other flaviviruses, ZIKV likely replicates in the midgut epithelial cells and subsequently the salivary gland cells. After an extrinsic incubation period of 5–10 days, ZIKV can be found in the mosquito’s saliva which can then infect humans. Moreover, the virus can likely be vertically transmitted transovariably as other flaviviruses. When the mosquito’s saliva containing ZIKV is inoculated into human skin, the virus can infect epidermal keratinocytes, skin fibroblasts in the subcutaneous layer, and the Langerhans cells. The keratinocytes and fibroblasts contain AXL, Tyro3, and TIM-1, which can serve as attachment factors or receptors for ZIKV. The Langerhans cells contain DC-SIGN, which can also serve as a receptor for virus entry. ZIKV infection of primary skin fibroblasts is associated with upregulation with TLR3 mRNA expression, and enhanced transcription of RIG-I and MDA5, which are known innate immune responses to RNA virus infection. This is followed by enhanced expression of interferon-alpha and -beta, and their downstream pathways of immune activation. Both types I and II interferons can suppress the viral load of infected cells. Moreover, ZIKV is capable of increasing its replication by the induction of autophagy in host cells. Thus, autophagy inhibitors can decrease the viral load of infected cells. Infected cells of human skin explant exhibit cytoplasmic vacuolation, pyknotic nuclei, and oedema in the stratum granulosum. After replication in

**Virology and pathogenesis**

ZIKV is an enveloped, positive-sense, single-stranded RNA virus belonging to the genus Flavivirus in the family Flaviviridae. It is closely related to Spondweni virus and the 2 viruses represent the only members of their clade within the mosquito-borne cluster of flaviviruses (Fig. 1). Phylogenetic analysis suggests that ZIKV has likely emerged between 1892 and 1943 in Uganda. The two major lineages of ZIKV are the African (subdivided into West and East African) and Asian lineages, which are responsible for causing the majority of infections in Africa and Asia (as well as the Pacific and Americas), respectively. The single-stranded RNA genome of ZIKV has a size of 10,794 nucleotides encoding 3419 amino acids, with 2 flanking untranslated regions (5' and 3' UTRs) and a single long open reading frame encoding a polyprotein, which is cleaved into capsid (C), precursor of membrane (prM), envelop (E), and 7 non-structural (NS) proteins (5'-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3'). Reverse transcription-polymerase chain reaction (RT-PCR) using primers targeting the E or NS5 gene is a key laboratory diagnostic tool for ZIKV infection in the recent outbreaks. The E protein is a major virion surface protein that is involved in receptor binding and membrane fusion. The domain III of E protein contains a panel of antigenic epitopes that are important targets of serological assays, neutralising antibodies, and vaccines. Loss of the N154 glycosylation site in the E protein may be associated with adaptation to mosquito vectors and thus facilitate transmission. A single amino acid mutation in the E protein (E1-A226V) of CHIKV has been reported to be associated with increased fitness of the virus in Ae. albopictus and allows CHIKV to disseminate in regions lacking the typical Ae. aegypti vector. The recent spread of the Asian lineage of ZIKV to Oceania and the Americas may be associated with significant NS1 codon usage adaptation to human housekeeping genes, which could facilitate viral replication and increase viral titres. Mutations in the E and NS1 genes should be detected in ZIKV strains causing the current epidemic.

When an infected Aedes mosquito bites an infected patient, it ingests a blood meal containing ZIKV. As in other flaviviruses, ZIKV likely replicates in the midgut epithelial cells and subsequently the salivary gland cells. After an extrinsic incubation period of 5–10 days, ZIKV can be found in the mosquito’s saliva which can then infect humans. Moreover, the virus can likely be vertically transmitted transovariably as other flaviviruses. When the mosquito’s saliva containing ZIKV is inoculated into human skin, the virus can infect epidermal keratinocytes, skin fibroblasts in the subcutaneous layer, and the Langerhans cells. The keratinocytes and fibroblasts contain AXL, Tyro3, and TIM-1, which can serve as attachment factors or receptors for ZIKV. The Langerhans cells contain DC-SIGN, which can also serve as a receptor for virus entry. ZIKV infection of primary skin fibroblasts is associated with upregulation with TLR3 mRNA expression, and enhanced transcription of RIG-I and MDA5, which are known innate immune responses to RNA virus infection. This is followed by enhanced expression of interferon-alpha and -beta, and their downstream pathways of immune activation. Both types I and II interferons can suppress the viral load of infected cells. Moreover, ZIKV is capable of increasing its replication by the induction of autophagy in host cells. Thus, autophagy inhibitors can decrease the viral load of infected cells. Infected cells of human skin explant exhibit cytoplasmic vacuolation, pyknotic nuclei, and oedema in the stratum granulosum. After replication in
<table>
<thead>
<tr>
<th>Transmission routes</th>
<th>Findings</th>
<th>Specific control measures</th>
<th>References</th>
</tr>
</thead>
</table>
| Blood transfusion  | • 2.8% (42/1505) of asymptomatic blood donors in French Polynesia (21 November 2013–17 February 2014) tested positive for ZIKV by RT-PCR. | • Endemic/epidemic areas:  
  - Universal nucleic acid testing of blood donors.  
  - Temporary discontinuation of blood donation (Importation of blood products from blood blank centres in non-endemic regions).  
  - Pre-donation questionnaire to identify donors with recent travel history to endemic/epidemic areas.  
  - Deferral of blood donors who have travelled to endemic areas within the preceding ≥14 days.  
  - Self-reporting of symptoms after blood donation (11/42 ZIKV-RT-PCR-positive donors developed symptoms 3–10 days after blood donation).  
|                    |          | • Non-endemic/epidemic areas:  
  - Use barrier methods unless trying to conceive.  
  - Individuals returning from endemic/epidemic areas should use barrier methods. | 75, 76, 77 |
| Semen              | • ZIKV was isolated by RT-PCR and viral culture (Vero cells) from the semen of a patient from French Polynesia (Tahiti) who presented with haematospermia.  
  • An American scientist acquired ZIKV infection in Senegal and developed prostatitis and haematospermia. After he returned to USA, his wife (never travelled to Africa and Asia) developed symptoms and serological evidence of ZIKV infection after having sexual intercourse with the index patient.  
  • The viral load in semen (10^7 copies/ml) may be higher than that in the concomitant urine (10^3 copies/ml) and serum (undetectable) samples, and may last for ≥62 days. | • Endemic/epidemic areas:  
  - Use barrier methods unless trying to conceive.  
  - Interval ultrasound assessment for prompt detection of intraterine complications.  
  - Some authorities advise women to delay becoming pregnant for at least 6–12 months.  
  - Avoid mosquito bites.  
|                    |          | • Non-endemic/epidemic areas:  
  - Avoid or defer travelling to endemic/epidemic areas.  
  - Avoid mosquito bites. | 14, 78, 144 |
| Perinatal/Transplacental | • At least 2 episodes of perinatal transmission reported in French Polynesia.  
  • Preliminary epidemiological and virological evidence support transplacental transmission of ZIKV leading to microcephaly and other congenital anomalies. | • Defer breastfeeding in infected mothers until virus clearance in breast milk and bodily fluids (eg: blood, urine, and saliva). | 78 |
| Breastfeeding      | • Breast milk samples of infected women inoculated on Vero cells were positive for viral RNA by RT-PCR, but replicative virus particles were not detected.  
  • Viral RNA can be detected in saliva of infected patients, but it is unknown whether replicative virus particles can be detected. | • Avoid exposure to saliva of infected patients until virus clearance. | 78, 79 |
| Saliva             |          |                          |            |
these local tissue cells and the regional lymph nodes, ZIKV may then disseminate from the lymphatics and bloodstream to reach other organs/tissues, including the central nervous system, the skeletal muscles, myocardium, and perhaps transplacentally to the foetus. ZIKV was highly neurotropic in infected suckling mice. The brains of infected suckling mice show neuronal degeneration, cellular infiltration, and softening in the brain with virus replication in astroglial cells and neurons on histopathological examination. Moreover, evidence of inflammation in skeletal muscles and myocardium has also been demonstrated in infected suckling mice. AXL and Tyro3 are members of the TAM family of receptor tyrosine kinases (RTKs). They are also present in neurons and under the influence of gonadotropin releasing hormone (GrH), which in turn may affect neuronal survival and migration. Furthermore, flaviviruses such as YFV may persist for up to 159 days after intracerebral inoculation in rhesus macaques. The neurotropism and persistence of ZIKV may therefore partially explain microcephaly and predominantly neurological complications and foetal anomalies in this suspected entity of congenital ZIKV infection.

### Clinical features and complications

Most patients with ZIKV infection are asymptomatic. In the outbreak of ZIKV infection on Yap Island, only 18% of cases were estimated to be symptomatic. The incubation period of ZIKV infection is unclear, but is estimated to be similar to other mosquito-borne flaviviruses (2–14 days). The clinical syndromes of symptomatic ZIKV infection can be broadly divided into Zika fever and congenital infection (“congenital Zika syndrome”) (Table 4).

#### Zika fever

Zika fever is an acute “dengue fever-like” illness characterized by low-grade fever (37.8–38.5°C), rash, retro-orbital headache, bilateral non-purulent conjunctivitis, myalgia, and arthritis/arthritis with periarticular oedema of the small joints of hands and feet. The rash in Zika fever is typically described as a generalized, erythematous, maculopapular rash that spreads downward from the face to the limbs. Less commonly, some patients may have more prominent systemic symptoms including high-grade fever, chills, rigours, sore throat, hypotension, and cervical, submandibular, axillary, and/or inguinal lymphadenopathies. Digestive tract symptoms including nausea, vomiting, diarrhoea, constipation, abdominal pain, and aphthous ulcers may also be present. Patients with genitourinary symptoms including haematuria, dysuria, perineal pain, and haematospermia often have detectable viral RNA or infectious virus particles in urine and/or semen. Haematological and biochemical laboratory parameters are usually normal. However, some patients may have transient and mild leucopenia, neutropenia, lymphopenia or activated lymphocytes, monocytosis, thrombocytopenia, and elevated serum levels of lactate dehydrogenase, aspartate aminotransferase, γ-glutamyl transferase, fibrinogen, ferritin, C-reactive protein, and erythrocyte sedimentation rate during the viraemic phase. Recovery from ZIKV infection is
associated with restoration of normal number of peripheral immune cells and normal function of antigen-presenting cells.45 Notably, the clinical manifestations of Zika fever are non-specific and may mimic those seen in infectious diseases caused by other arthropod-borne pathogens, especially DENV and CHIKV. Some suggest that Zika fever may be distinguished from dengue fever and Chikungunya fever by more prominent oedema of the extremities, less severe headache and malaise, and milder degree of thrombocytopenia seen in the former.13,115 Moreover, haemorrhagic complications seen in dengue fever have not been reported in Zika fever, and arthralgia in Zika fever is less severe than that in Chikungunya fever.13 However, none of these features are pathognomonic and laboratory confirmation is required to exclude co-infections with these arboviruses and other causes of acute febrile illness in returned travellers from endemic regions, such as malaria.

Zika fever is usually self-limiting with most clinical manifestations resolving completely within 3–7 days.13,49,116 No death, hospitalisation, or haemorrhagic complication was reported during the outbreak on Yap Island.13 However, some patients may experience more protracted symptoms and other non-haemorrhagic complications. Zika fever-related rash usually resolve within the first week, but may last for up to 14 days and may be pruritic.13 Other exanthematous diseases, such as DENV, CHIKV, rubella virus, measles virus, parvovirus B19, adenovirus, enterovirus, and rickettsial infection, should be excluded. The median duration of arthralgia is 3.5 days, but some patients may develop persistent or recurrent arthralgia for more than a month after symptom onset, mimicking the post-infectious chronic arthritis seen in Chikungunya fever and Lyme disease.13,76 Lymphadenopathies may be present for 2 weeks after symptom onset, and alternative diagnoses such as infectious mononucleosis-like syndrome, Streptococcus pyogenes infection, and toxoplasmosis should be considered in refractory cases.45 A post-infection asthenia appears to be frequent and further investigations may be necessary to determine possible association between ZIKV infection and chronic fatigue syndrome.13,117,118 Immune-thrombocytopenic purpura and cardiac complication have also been reported in a few cases.114 Jaundice was observed in patients with virological and/or serological evidence of ZIKV infection in Eastern Nigeria in the 1950s who had co-infections (malaria and microfilaraemia) and a patient with sickle cell anaemia.17,119

A possible association between ZIKV infection and severe neurological complications has been proposed during the recent epidemics in Oceania and South America, during which the incidence of Guillain–Barré syndrome has increased by 8–20 times in French Polynesia.115,120 74/8750 (0.8%) patients with suspected ZIKV infection in the French Polynesia outbreak developed neurological syndromes after presenting with a Zika fever-like illness.120 Forty-two of these 74 (56.8%) patients were diagnosed with Guillain–Barré syndrome.12,51,121 Similarly, Guillain–Barré syndrome has been reported among patients with Zika fever-like illness in South America.51,121 Other neurological complications potentially linked to ZIKV infection include encephalitis, meningencephalitis, myelitis, paraesthesia, vertigo, facial paralysis, and

---

Figure 1  Phylogenetic tree of selected ZIKV strains with partial nucleotide sequences of Envelope gene. The tree was constructed by the maximum likelihood method using PhyML with automatic model selection by SMS (beta version, online execution http://www.atgc-montpellier.fr/phyml-sms/). The best model in each tree was calculated and selected automatically. aLRT was applied and only those branches with over 75% aLRT values are shown in the trees. Viruses are labelled as follow: virus name/strain/accession number/host/location/region/year. DENV1, Dengue virus 1; JEV, Japanese encephalitis virus; SPOV, Spondweni virus; TBEV, tick-borne encephalitis virus; WNV, West Nile virus; YFV, Yellow fever virus; ZIKV, Zika virus.
Table 4  Clinical features and complications of ZIKV infection.

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Comments</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Asymptomatic</strong></td>
<td>&gt;80% of infected human are asymptomatic.</td>
<td>13</td>
</tr>
<tr>
<td><strong>Zika fever</strong></td>
<td>Fever, chills, rigours, malaise, headache, retro-orbital pain, anorexia, sore throat, lymphadenopathy (cervical, submandibular, axillary, and/or inguinal), hypotension, and conjunctivitis.</td>
<td>19, 45, 76, 150</td>
</tr>
<tr>
<td>Systemic</td>
<td>Guillain–Barre syndrome, encephalitis, meningoencephalitis, paraesthesia, photophobia, vertigo, hypertensive iridocyclitis, auditory (bilateral dull and metallic hearing), facial paralysis, and myelitis.</td>
<td>48, 76, 114, 115, 120, 121, 152</td>
</tr>
<tr>
<td>Neurological/Ophthalmological</td>
<td>Myalgia, arthralgia with periarticular oedema (wrists, knees, ankles, and small joints of the hands and feet).</td>
<td>13, 45, 76</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Nausea, vomiting, diarrhoea, constipation, abdominal pain, and jaundice.</td>
<td>13, 17, 19, 119</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Haematuria, prostatitis (perineal pain and mild dysuria), and haematospermia.</td>
<td>76, 77</td>
</tr>
<tr>
<td>Dermatological/mucocutaneous</td>
<td>Diffuse maculopapular rash, pruritis, aphthous ulcer, and gingival bleeding.</td>
<td>13, 76</td>
</tr>
<tr>
<td>Haematological</td>
<td>Leucopenia, neutropenia, lymphopenia or activated lymphocytes, monocytosis, thrombocytopenia, and elevated erythrocyte sedimentation rate; and immune-thrombocytopenic purpura.</td>
<td>41, 43, 45, 97, 114</td>
</tr>
<tr>
<td>Biochemical</td>
<td>Elevated serum lactate dehydrogenase, aspartate aminotransferase, $\gamma$-glutamyl transferase, C-reactive protein, fibrinogen, and ferritin levels.</td>
<td>29, 42</td>
</tr>
<tr>
<td>Death</td>
<td>At least 3 deaths: An adult male with systemic lupus erythematosus on cortcosteroids, rheumatoid arthritis, and alcoholism. A 15-year-old girl with sickle cell disease who developed disseminated infection with fever, respiratory distress, jaundice, and hepatosplenomegaly. A neonate with microcephaly, foetal anasarca, and polyhydramnios who died within the first five minutes of birth.</td>
<td>51, 121, 119</td>
</tr>
</tbody>
</table>

**Suspected “congenital Zika syndrome”**

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>General:</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low birth-weight, reduced foetal movement, excessive/redundant scalp skin, foetal anasarca, polyhydramnios, and arthrogryposis; may be associated miscarriage.</td>
<td>14, 51, 121, 122, 125-127</td>
</tr>
</tbody>
</table>

**Neurological:**
- Microcephaly, polymalformative syndromes, brainstem dysfunction, and absence of swallowing.

**Ophthalmological:**
- Cataract, asymmetrical eye sizes, intraocular calcifications, macular alterations (gross pigment mottling and/or chorioretinal atrophy), optic nerve abnormalities (hypoplasia with double-ring sign, pallor, and/or increased cup-to-disk ratio), iris coloboma, and lens subluxation.

| Ultrasonographic features | Brain atrophy, widespread brain calcifications (periventricular, cerebral parenchyma, thalami, and basal ganglia), lissencephaly, pachygyria, dysgenesis of corpus callosum, vermis, and thalami, enlarged cisterna magna, asymmetrical cerebral hemispheres, severe unilateral ventriculomegaly secondary to cortical/subcortical atrophy, displacement of the midline, and thinning of the parenchymal on the dilated side, thin pons and brainstem. | 14, 121, 128 |

(continued on next page)
ophthalmological (photophobia and hypertensive iridocyclitis) and auditory manifestations.\textsuperscript{48,76,114,115,120–122} Suspected fatalities due to ZIKV-related Guillain–Barre\textsuperscript{ syndrome have been reported.\textsuperscript{123} While the neurotropism of ZIKV may partially explain these neurological manifestations, more details and serial studies on their cerebrospinal fluid and magnetic resonance images by case-control studies are required to ascertain their association.

Zika fever-related death appears to be extremely rare but a number of probable cases have been reported, especially among immunocompromised patients and neonates with suspected congenital ZIKV infection.\textsuperscript{51,119,121} A small number of patients with coinfection with DENV or HIV did not appear to have more severe disease.\textsuperscript{29,124} Further studies should be conducted to identify patients who are at risk of severe disease or death.

### Congenital Zika syndrome

Microcephaly (head circumference $\geq 2$ standard deviations below the mean for sex and gestational age at birth) is the most prominent and commonly reported clinical feature of suspected congenital Zika syndrome.\textsuperscript{14,125} Besides microcephaly, neonates and foetuses with suspected congenital ZIKV infection also had other malformations (Table 4). General features included low birth-weight, redundant scalp skin, anasarca, polyhydramnios, and arthrogryposis. Neurological abnormalities included cerebral lesions, polymalformative syndromes, brainstem dysfunction, and absence of swallowing.\textsuperscript{51} Ophthalmological defects included cataract, asymmetrical eye sizes, intraocular calcifications, macular atrophy (well-defined macular neuroretinal atrophy and/or macular pigment mottling and foveal reflex loss), optic nerve hypoplasia, iris coloboma, and lens subluxation.\textsuperscript{122,126,127} Notably, other features characteristic of intrauterine infections, such as hepatosplenomegaly, rash, and chorioretinitis have not been reported.\textsuperscript{14} Ultrasonographic examination revealed cerebral atrophy, intracranial calcifications especially over the white matter of frontal lobes, caudate, lentostriatal vessels, cerebellum, or around the lateral and fourth ventricles, dysgenesis of corpus callosum, vermis, and thalami, enlarged cisterna magna, asymmetrical cerebral hemispheres, severe unilateral ventriculomegaly, displacement of the midline, and thinning of the parenchyma on the dilated side, pons and brainstem.\textsuperscript{14,51,121,128} ZIKV particles and RNA may be detected by electron microscopy and RT-PCR, respectively, in autopsied samples.\textsuperscript{125}

Two important questions concerning congenital ZIKV infection remain unanswered. The first question is whether ZIKV is indeed the cause of microcephaly and other congenital anomalies in these patients. Severe consequences have been reported for materno-foetal transmission of other arboviruses, such as dengue virus (preterm delivery, foetal death, low birth-weight, prematurity, acute foetal distress during labour), WNV (chorioretinitis and focal cerebral destruction), and CHIKV (encephalopathy and haemorrhagic fever).\textsuperscript{80,82,86} Preliminary analysis in the current epidemic of microcephaly has not yet completely excluded other infectious or environmental aetiologies.\textsuperscript{51} Moreover, there is some virological evidence to support the association between congenital ZIKV infection and these anomalies. ZIKV RNA
has been detected by RT-PCR in the amniotic fluid of 2 pregnant women whose foetuses had ultrasonographic evidence of microcephaly, in the blood and foetal tissues of a neonate with microcephaly and other congenital anomalies who died within the first 5 min of birth, and in the neonatal brain tissues of a few cases of full-term miscarriages and neonates with microcephaly. However, there is still no large-scale prospective cohort or case-control study to demonstrate a causal link between the presence of ZIKV in the foetus and the congenital anomalies after exclusion of other infectious and toxic causes. Some have suggested that the apparent microcephaly surge might be attributable to the intense search for cases due to the heightened awareness of a possible association with the ZIKV outbreak or the use of larvicide. Furthermore, detailed investigations for exclusion of other pathogens associated with congenital malformations have only been reported in a small number of cases. Microcephaly is well reported in congenital cytomegalovirus, rubella virus, and varicella zoster virus infection. Chorioretinitis and intracranial calcifications are common in congenital cytomegalovirus infection and toxoplasmosis, but the latter is more commonly associated with hydrocephalus. Cataract and cardiac anomalies are characteristic of congenital rubella syndrome, although cataract can also be found in congenital herpes simplex virus infection. Thus, the diagnosis of congenital Zika syndrome would depend on the exclusion of these "TORCH" infections in future studies using clinical criteria, histopathological findings, and serological, molecular and conventional cell culture techniques.

If ZIKV is eventually confirmed to be the cause of these congenital anomalies, the second key question would be whether congenital Zika syndrome actually comprises a wider spectrum of varying clinical severities than that seen in the reported cases. As with other congenital infections, it is possible that the reported cases of microcephaly represent only the tip of the iceberg, focussing on the more severely affected patients, and that the timing of infection is likely to be important in determining the severity and outcome of the affected foetus. Early infection during the first or second trimester of pregnancy may be associated with congenital anomalies or even intrauterine death. Indeed, preliminary data suggested that the greatest risk of microcephaly or congenital anomalies in the affected neonates appears to be associated with ZIKV infection in the first trimester of pregnancy. Of 35 mothers with infants born with microcephaly, 57% and 14% had a rash during the first and second trimester of pregnancy, respectively. Besides neurological defects, cardiac and muscular abnormalities should also be excluded, as sucking mice infected with ZIKV developed evidence of central nervous system infection, myositis and myocarditis. Some suspected cases of congenital Zika syndrome developed severe arthrogryposis. Neonates with probable perinatal transmission of ZIKV infection appear to have mild disease and favourable outcome. Further investigations should be conducted to better define the spectrum of manifestations in different gestational stages of congenital ZIKV infection.

Laboratory diagnosis

Definitive diagnosis of ZIKV infection requires laboratory confirmation as there are no pathognomonic clinical, biochemical, or radiological features that reliably distinguish Zika fever from other arboviruses, and congenital ZIKV infection from other infective, toxic, or genetic causes of congenital anomalies. Successful isolation of ZIKV in viral culture, the gold-standard of laboratory diagnosis of viral infections, mainly depends on the timing of specimen collection and viral loads in the specimens. ZIKV has been isolated in Vero and Vero E6 cells inoculated with infected patients' serum, urine, and/or semen samples (Table 5). However, infectious virus particles were not recovered by culture in most specimens with low viral loads. A positive serum immunoglobulin (Ig) M or 4-fold rise in the titre of neutralising antibodies in paired serum samples collected approximately 2 weeks apart also establishes the diagnosis of ZIKV infection. IgM may be detected by enzyme-linked immunoassay on as early as day 3 of symptom onset and may last for over 2 months. IgM antibodies to DENV and WNV usually persist for ≤3 months and ≤5 months, respectively. The major limitation of these serological tests is possible cross-reactivity with other flaviviruses. Neutralising antibodies detected by plaque-reduction neutralisation test may be more specific than IgM detection by ELISA for primary ZIKV infection, but may also have indeterminate results for secondary infection, including patients with previous vaccination against or exposed to other flaviviruses. This is especially problematic in areas where there is co-circulation of multiple flaviviruses with the same Aedes mosquito vectors. Patients with primary ZIKV infection and past DENV infection are more likely to have higher titre (usually ≥4-fold) of IgM and/or neutralising antibodies against ZIKV than against DENV or other flaviviruses. A positive serum DENV NS1 antigen test without serial increase in IgM or the combination of a positive IgM response to DENV and lack of an IgG seroconversion in the convalescent-phase serum sample should prompt the clinician to investigate for another flavivirus such as ZIKV. Moreover, co-infections with other mosquito-borne arboviruses, such as DENV, CHIKV, WNV, and Japanese encephalitis virus, are always possible and should be excluded by more extensive laboratory testing if clinically indicated.

Rapid and accurate diagnosis of ZIKV infection during the recent epidemics has mainly been achieved by the application of RT-PCR using primers that target the E or NS5 gene of ZIKV. Alternatively, RT-PCR sequencing using universal primers that target the conserved regions in the genomes, such as the NS5 gene, of multiple flaviviruses, may allow simultaneous detection of >50 different flaviviruses. Serum samples should be collected in the early phase of the disease, because viraemia is usually short-lived (usually ≤5 days, rarely up to 11 days) and may be low-level (<10^2 copies/ml). Alternatively, urine and semen samples may have higher viral RNA loads.
Table 5 Advantages, limitations, and uses of different diagnostic tests and types of specimens for laboratory diagnosis of ZIKV infection.14,40,41,49,50,75–79,96,97,102,121,125,127,137,139,153

<table>
<thead>
<tr>
<th>Specimen types</th>
<th>Laboratory diagnostics</th>
<th>Viral culture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td>• Most cases have short-lived (&lt;5 days of symptom onset) and low-level viraemia.</td>
<td>• Infectious ZIKV has been detected in human blood collected on as early as the day of symptom onset (Vero cells)</td>
</tr>
<tr>
<td></td>
<td>• Rarely, viral RNA may be detected in serum on as late as 11 days of symptom onset.</td>
<td>• 3/34 (8.8%) of archived serum samples which were RT-PCR-positive for ZIKV yielded infectious viral particles in Vero cells</td>
</tr>
<tr>
<td>Urine</td>
<td>• Higher viral load than concomitant serum samples.</td>
<td>• Successful isolation Vero E6 cells; may be especially useful in patients with genitourinary symptoms.</td>
</tr>
<tr>
<td></td>
<td>• Positive from day 2–3 to after day 30 of symptom onset.</td>
<td></td>
</tr>
<tr>
<td>Semen</td>
<td>• Higher viral load (10^7 copies/mL) than concomitant urine (10^4 copies/mL) and serum (undetectable) samples.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• May be positive for ≥62 days of symptom onset.</td>
<td></td>
</tr>
<tr>
<td>Nasopharyngeal swab</td>
<td>• Positive in a patient whose concomitant serum and wound (monkey bite) samples were negative.</td>
<td>• May be complimentary to serum and urine for suspected ZIKV infection.</td>
</tr>
<tr>
<td>Saliva</td>
<td>• Viral RNA is more frequently detected in saliva than blood.</td>
<td>• May be complimentary to serum and urine for suspected ZIKV infection.</td>
</tr>
<tr>
<td></td>
<td>• Positive in both neonates and adults.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Complimentary but cannot replace serum samples.</td>
<td></td>
</tr>
<tr>
<td>Amniotic fluid</td>
<td>• Positive in two pregnant women whose foetuses had ultrasonographic evidence of microcephaly.</td>
<td>• May be useful in infants with suspected congenital ZIKV infection.</td>
</tr>
<tr>
<td>Foetal/placental/umbilical cord tissue</td>
<td>• Positive in a neonate with congenital anomalies (microcephaly, foetal anasarca, and polyhydramnios) who died within the first 5 min of life.</td>
<td>• May be useful in infants with suspected congenital ZIKV infection.</td>
</tr>
<tr>
<td>Cerebrospinal fluid</td>
<td>• May be useful in infants with suspected congenital ZIKV infection or patients with neurological complications.</td>
<td>• May be useful in infants with suspected congenital ZIKV infection or patients with neurological complications.</td>
</tr>
<tr>
<td>Skin biopsy</td>
<td>• May be useful to exclude concomitant infections in patients with persistent or atypical rash.</td>
<td>• May be useful to exclude concomitant infections in patients with persistent or atypical rash.</td>
</tr>
<tr>
<td>Joint fluid</td>
<td>• May be useful to exclude concomitant infections in patients with persistently persistent or recurrent arthritis.</td>
<td>• May be useful to exclude concomitant infections in patients with persistently persistent or recurrent arthritis.</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>• May be useful to exclude concomitant infections in patients with unusually persistent or severe cytopenia.</td>
<td>• May be useful to exclude concomitant infections in patients with unusually persistent or severe cytopenia.</td>
</tr>
<tr>
<td>Other tissues</td>
<td>• Brain, liver, spleen, and pooled visceral (kidney, lung, and heart) tissues were positive in a fatal case (an adult male with co-morbidities and immunosuppressive treatment).</td>
<td>• May be useful to exclude concomitant infections in patients with unusually severe or fatal infection.</td>
</tr>
</tbody>
</table>

Abbreviations: RT-PCR, reverse transcription-polymerase chain reaction; ZIKV, Zika virus.
(>10^6 copies/ml) than serum samples, and may be persistently positive for >30 days and >62 days after symptom onset, respectively. In a few cases, ZIKV RNA has also been detected in saliva and nasopharyngeal swab samples of patients whose serum samples tested negative for ZIKV. These samples should therefore also be collected in suspected cases of ZIKV infection. Collection of amniotic fluid should be considered in pregnant women with positive ZIKV test result or if the foetuses show ultrasonographic evidence suggestive of congenital ZIKV infection. Cerebrospinal fluid, placental, and/or umbilical cord tissues from neonates with suspected congenital ZIKV infection should be sent for virological and/or histopathological examinations to establish the diagnosis. ZIKV RNA may also be detected in organ tissues in the rare cases of suspected ZIKV-related deaths. Future studies should aim to better stratify the clinical use of these tests and to develop point-of-care tests (eg: antigen tests) that can be widely used in less developed regions without the facilities and expertise for molecular or serological tests.

**Clinical management and perinatal care**

Treatment is usually not required for patients with asymptomatic or uncomplicated Zika fever. The mainstay of treatment is supportive as there are no specific anti-ZIKV antiviral agents. Acetaminophen may be used to relieve fever and arthralgia. Anti-histamines may help to control pruritus. Adequate rehydration for fluid loss through sweating, vomiting, and insensible losses should be encouraged. Aspirin should be avoided due to the risks of bleeding in those with thrombocytopenia and developing Reye’s syndrome in children less than 12 years of age. Nonsteroidal anti-inflammatory drugs are also contraindicated in cases where DENV and CHIKV infections cannot be confidently excluded in order to avoid haemorrhagic complications. Potential neurological complications, especially Guillain–Barré syndrome, should be diagnosed promptly to allow early use of intravenous immunoglobulins and/or plasmapheresis. The risk of immune enhancement should also be considered if convalescent-phase plasma therapy with neutralising antibodies against ZIKV is used for treatment of severe cases.

Virological testing and foetal ultrasound to exclude ZIKV infection and foetal microcephaly or intracranial calcifications should be offered to pregnant women who develop Zika fever-like symptoms during or within 2 weeks of travel to areas with ZIKV transmission. Besides collecting the appropriate specimens for virological tests, serial foetal ultrasound examinations should be performed every 3–4 weeks to monitor foetal anatomy and growth in suspected cases of congenital ZIKV infection. Foetal ultrasound and/or aminocentesis should also be offered to asymptomatic and seropositive pregnant women with history of travel to affected areas. After delivery, serum should be collected either from the umbilical cord or directly from the neonate within 2 days of birth for RT-PCR, IgM and/or neutralising antibodies against ZIKV. Comprehensive physical examination including measurement of the occipitofrontal circumference, length, and weight, evaluation for neurological abnormalities, dysmorphic features, hepatosplenomegaly, rash, ophthalmological lesions, and auditory defects, and laboratory testing for TORCH screening should be performed. The affected child and the family should be managed and counselled by a multidisciplinary team consisting of paediatric neurologist, clinical geneticist or dysmorphologist, infectious disease specialist, medical social worker, and other relevant specialists. Long-term follow-up to monitor physical, intellectual, and functional progress of the child should be offered.

**Epidemic and infection control**

Both vector control and personal preventive measures are important for interrupting the transmission of ZIKV. Systematic mosquito surveillance and control programs should be established and coordinated by health authorities. Mass sanitation campaigns to eliminate mosquito breeding sites in household and high-risk areas such as garbage collection points, construction sites, illegal dumping grounds, and invalid car fields should be organised. Mosquitoes should be removed with a radius of at least 400 m around areas with high population densities, such as schools, transport terminals, churches, and healthcare facilities. In areas where autochthonous or imported cases of ZIKV are detected, the use of adulticide through spraying to remove infected adult mosquitoes should be considered. Residents in or travellers to affected areas should stay indoor with air conditioning, window and door screens if possible, wear long sleeves and pants, use permethrin-treated clothing and gear, and use insect repellents when outdoor. Most Environmental Protection Agency (EPA)-registered insect repellents, including N,N-diethyl-m-toluamide (DEET), should be safe for pregnant and lactating women (20% DEET) and children (10% DEET) aged >2 months. Individuals returning from affected areas to non-affected regions should continue to use insect repellents for at least an additional 14 days to prevent local non-infected mosquitoes from the acquisition of virus from the asymptomatically infected returned travellers. This will serve to interrupt the mosquito-human-mosquito transmission chain. Hospitalised laboratory-confirmed cases should be managed in designated wards to avoid mosquito bites. The effects of other novel mosquito-control measures, such as the Wolbachia biological control approach, should be evaluated. Other animals such as roosters should also be investigated as potential animal reservoirs and controlled as findings indicate.

Non-vector-borne transmission of ZIKV may be prevented by specific measures (Table 3). Concerning blood transfusion, universal nucleic acid testing of blood donors is recommended. The use of universal primers that can simultaneously detect multiple arboviruses such as DENV and ZIKV should be considered. Temporary discontinuation of blood donation should be considered during an outbreak situation. In non-endemic areas, pre-donation questionnaire to identify donors with recent travel history to regions with reported cases of ZIKV infection and deferral of blood donation from these donors until at least 14 days after returning from affected regions should be implemented. Most transfusion-related transmissions of arboviruses are
associated with asymptomatic infections, and symptomatic donors who were RT-PCR-positive for ZIKV usually developed symptoms between 3 and 10 days after blood donation.\textsuperscript{143} Newer pathogen reduction technologies for blood products should be considered.\textsuperscript{143} Similarly, donated organs, especially kidneys, from individuals with travel history to areas affected by ZIKV should be tested for ZIKV as the virus may persist in the genitourinary tract for an undetermined period.\textsuperscript{40,41,49,50,97} Barrier methods should be used to prevent sexual transmission through infected semen. Male returned travellers should continue the use of condom with pregnant sex partner throughout the whole duration of pregnancy. Future studies should evaluate the duration of virus shedding in semen and the infectiousness of RNA-positive semen samples, in order to determine how long barrier methods should be used by men returning to non-endemic regions. Some regional authorities have advised women to avoid pregnancy until the epidemic is over.\textsuperscript{144} Pregnant women or those planning for pregnancy should defer travelling to regions with reported cases of ZIKV infection. If such travel was unavoidable, they should strictly comply with personal protective measures to avoid mosquito bites. Further studies are needed to determine the risk of ZIKV transmission by breast milk and saliva. Other less common transmission routes, including mucocutaneous exposure to infected bodily fluid during laboratory and patient-care procedures, and bites by infected patients should be avoided with strict compliance to infection control measures. In the laboratory setting, ZIKV can be killed by potassium permanganate, ether, and heat (\(>60^\circ\text{C}\)), but it is not effectively neutralised with low concentration (10\%) of ethanol.\textsuperscript{54}

No ZIKV vaccine is available currently. Because the moratorium for pregnancy may be impractical for some people, a safe and effective ZIKV vaccine is urgently needed. Some realistic approaches include live-attenuated or killed vaccine from human cell lines (as in the case of YFV and Japanese encephalitis vaccines), attenuated chimeric vaccine (DENV vaccine using the YFV vaccine backbone, currently in Phase III clinical trial), DNA and recombinant protein vaccine.\textsuperscript{145} Suitable animal models for evaluation of these potential vaccine candidates should be developed for ZIKV infection. The role of passive immunisation before and after exposure to ZIKV should also be assessed in future studies.

**Conclusion**

The ZIKV epidemic has emerged as an unexpected global health emergency as the rapidly expanding ZIKV epidemic may turn out to be a major cause of permanent and severe disability in a generation of newborns, which would constitute a huge socioeconomic burden to the affected countries. The future of the ZIKV epidemic is unpredictable, but the worldwide spread of DENV and CHIKV over the past two decades suggests that ZIKV has the potential to follow their paths. With more than half of the world’s human population living in areas infested with *Aedes* mosquitoes, the ongoing adaptation of ZIKV to an urban cycle signify the virus’ pandemic potential.\textsuperscript{36} Research preparedness is urgently needed to improve mosquito-control measures, as well as to develop point-of-care laboratory diagnostics, antivirals, and vaccines which are suitable for use in pregnant women and foetuses.

**Conflict of interest**

The authors declare no conflict of interest.

**Acknowledgements**

The study was partly supported by the Consultancy Service for Enhancing Laboratory Surveillance of Emerging Infectious Disease of the Department of Health, The Food and Health Bureau, Hong Kong Special Administrative Region, China; and by the donations of Hui Hoy and Chow Sin Lan Charity Fund Limited and Mr. Larry Chi-Kin Yung.

**References**


59. Haddow AJ, Williams MC, Woodall JP, Simpson DJ, Goma LK. Tissue isolation of Zika virus from *Aedes (Stegomyia) Afri


118. vera CA, Maia M, Bravo-Filho V, Gois AL, Belfort JR. Zika virus in Brazil and macular atrophy in a child with microcephaly. Lancet 2016;387(10015):228.


